Cargando…
Early lesion detection with (18)F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer
PURPOSE: Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used in patients with biochemically recurrent prostate cancer (BCR), mostly using gallium-68 ((168)Ga)-labelled radiotracers. Alternatively, fluorine-18 ((18)F)-labelled PSMA tracers are available, such as (18)F-DCFPyL, which...
Autores principales: | Wondergem, M., Jansen, B. H. E., van der Zant, F. M., van der Sluis, T. M., Knol, R. J. J., van Kalmthout, L. W. M., Hoekstra, O. S., van Moorselaar, R. J. A., Oprea-Lager, D. E., Vis, A. N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647179/ https://www.ncbi.nlm.nih.gov/pubmed/31230088 http://dx.doi.org/10.1007/s00259-019-04385-6 |
Ejemplares similares
-
Clinical verification of (18)F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer
por: Meijer, Dennie, et al.
Publicado: (2020) -
Optimization and validation of (18)F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer
por: Luining, Wietske I., et al.
Publicado: (2023) -
Pelvic lymph-node staging with (18)F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -
por: Jansen, B. H. E., et al.
Publicado: (2020) -
Machine learning-based analysis of [(18)F]DCFPyL PET radiomics for risk stratification in primary prostate cancer
por: Cysouw, Matthijs C. F., et al.
Publicado: (2020) -
Management impact of (18)F-DCFPyL PET/CT in hormone-sensitive prostate cancer patients with biochemical recurrence after definitive treatment: a multicenter retrospective study
por: Meijer, Dennie, et al.
Publicado: (2021)